We determined the optimal dose schedule of dex during manufacturing that upregulated IL-7Rα on CAR T cells, improving their responsiveness to IL-7, but did not impact CAR T cell expansion, phenotype, or function in vitro, or anti-tumor activity in multiple in vivo tumor models of both hematologic and solid malignancies. Here, IL7R is linked to neoplasm.